Key result
Double heterozygosity for Factor V Leiden and Factor II G20210A mutations was associated with a substantially increased risk of venous thromboembolism.
Why the study?
Does the presence of both Factor V Leiden and Factor II G20210A mutations increase the risk of venous thromboembolism compared to controls?
Meta-Analysis (n=5,514)
Yes
Does the presence of both Factor V Leiden and Factor II G20210A mutations increase the risk of venous thromboembolism compared to controls?
Answers are grounded in this paper and cite their sources.
The combined presence of Factor V Leiden and Factor II G20210A mutations synergistically increases the risk of venous thromboembolism by 20-fold.
Summary Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23% of patients heterozygous for factor II G20210A were also heterozygous for factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptive (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of factor V Leiden was lower in patients with pulmonary embolism than in patients with deep vein thrombosis without PE (odds ratio 0.69). Conversely, factor II G20210A mutation was equally balanced in both patient groups.
No takes yet. Share an insight, caveat, or question.
Rosendaal et al. (2001) conducted a meta-analysis in Venous Thromboembolism (n=5,514). Double heterozygosity for Factor V Leiden and Factor II G20210A mutations vs. Controls without double heterozygosity was evaluated on Venous thromboembolism (OR 20.0, 95% CI 11.1-36.1). Double heterozygosity for Factor V Leiden and Factor II G20210A mutations was associated with a substantially increased risk of venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: